Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanHKSE:02268 +1.86%50 FCF Yield % is 0.64 as of Sep. 01, 2026. GuruFocus rates HKSE:02268 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 57.01% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for WuXi XDC Cayman's FCF Yield % or its related term are showing as below:
HKSE:02268'
s FCF Yield % Range Over the Past 10 Years
Min: -2.34 Med: -0.98 Max: 0.93
Current: 0.64
During the past 6 years, the highest FCF Yield % of WuXi XDC Cayman was 0.93%. The lowest was -2.34%. And the median was -0.98%.
HKSE:02268's FCF Yield % is ranked better than 57.01% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.615
vs HKSE:02268: 0.64
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
WuXi XDC Cayman FCF Yield % Related Terms
WuXi XDC Cayman FCF Yield % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02268 vs TMO, DHR, NTRA: FCF Yield % Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's FCF Yield % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (HKSE:02268) has a FCF Yield % of 0.64 as of Sep. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on WuXi XDC Cayman and its competitors. According to the industry distribution chart, WuXi XDC Cayman ranks #92 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 43%.
Is WuXi XDC Cayman's FCF Yield % too high?
WuXi XDC Cayman's current FCF Yield % is 0.64. Based on the distribution chart, WuXi XDC Cayman ranks #92 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #92 out of 214 companies for FCF Yield %. This puts WuXi XDC Cayman in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current FCF Yield % is 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current FCF Yield % of 0.64. The current FCF Yield % is 0.64. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current FCF Yield % is 0.64 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
